共 3 条
[1]
42 Results of a one-year international phase IIB trial of LDT; and LDT plus lamivudine; in patients with chronic hepatitis B.[J].S.H. Han;N.W.Y. Leung;E.K. Teo;M. Tong;F. Wong;H.W. Hann;T. Poynard;N.A. Brown;M. Myers;G. Chao;D. Lloyd;C.L. Lai.Journal of Hepatology.2004,
[2]
439 Improving antiviral therapy in chronic hepatitis B: Maximal viral suppression at week 24 correlates with better clinical efficacy at one year.[J].T. Poynard;C.L. Lai;N.W.Y. Leung;E.K. Teo;M. Tong;F. Wong;H.W. Hann;S. Han;M. Myers;G. Chao;D. Lloyd;N.A. Brown.Journal of Hepatology.2004,
[3]
452 Clinical pharmacokinetics of telbivudine; a potent antiviral for hepatitis B; in subjects with impaired hepatic or renal function.[J].X.J. Zhou;M. Myers;G. Chao;G. Dubuc;N. Brown.Journal of Hepatology.2004,